This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bernard, B. K. Articles by Mennear, J. H. Search for Related Content PubMed PubMed Citation Articles by Bernard, B. K. Articles by Mennear, J. H. Social Bookmarking                         What's this?

Studies of the Toxicological Potential of Tripeptides (L-Valyl-L-prolyl-L-proline and L-Isoleucyl-L-prolyl-L-proline): II. Introduction

SRA International Inc., Washington, DC, USA

Yasunori Nakamura

Product Development Laboratory, Calpis Co., Ltd., Sagamihara, Kanagawa, Japan

Izuki Bando

Quality Assurance Department, Calpis Co., Ltd., Sagamihara, Kanagawa, Japan

John H. Mennear

Campbell University, School of Pharmacy, Buies Creek, North Carolina, USA

Correspondence: Address correspondence to Bruce K. Bernard, PhD, President, SRA International, Inc., 1920 L Street, NW, Suite 420, Washington, DC 20036, USA. E-mail:bernard{at}sra-intl.com

The consumption of fermented milk to maintain good health, including the maintance of normal blood pressure, is an ancient tradition in a number of areas of the world (e.g., East Asia, France). Recent studies have suggested that fermented milk has a normotensive effect in hypertensive rats and humans, but no effect on blood pressure in normotensive rats and humans. Two tripeptides, L-valyl-L-prolyl-L-proline (VPP) and L-isoleucyl-L-prolyl-L-proline (IPP), have been identified as possessing significant angiotensin-converting enzyme inhibitory activity and are therefore believed to be the source of the normotensive effects. This document, the second of nine chapters, provides information on these two tripeptides, including physical/chemical properties, molecular weights, chemical structures, normal consumption in the diet, manufacturing information, regulatory approval in Japan, and Japanese consumption of food containing enhanced levels of VPP plus IPP. In addition, the results of studies in rats and humans conducted to evaluate the effect of these substances on blood pressure are presented. The research suggests that in adult normotensive volunteers, consumption of up to 7.92 mg of VPP and 4.52 mg IPP daily for 2 weeks causes neither clinical signs nor biologically meaningful effects on systolic or diastolic blood pressure, pulse rate, or clinical pathology (serum chemistry or hematology). However, when a similar study was performed using mildly and moderately hypertensive adults as subjects and they consumed 2.52 mg of VPP and 1.64 mg of IPP per day, a significant drop in systolic blood pressure was detected for a prolonged time interval. This chapter also introduces the issue of safety testing for these substances and describes the information to be found in the subsequent seven chapters.

Key Words: Food Ingredient • Generally Recognized as Safe (GRAS) • IPP • Normotensive Effects • Tripeptides • VPP

International Journal of Toxicology, Vol. 24, No. 4 Suppl, 5-11 (2005)
DOI: 10.1080/10915810500259531


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Maeno, Y. Nakamura, J. H. Mennear, and B. K. Bernard Studies of the Toxicological Potential of Tripeptides (L-Valyl-L-prolyl-L-proline and L-Isoleucyl-L-prolyl-L-proline): III. Single-and/or Repeated-Dose Toxicity of Tripeptides-Containing Lactobacillus helveticus-Fermented Milk Powder and Casein Hydrolysate in Rats International Journal of Toxicology, July 1, 2005; 24(4_suppl): 13 - 23. [Abstract] [Full Text] [PDF]

				Y. Nakamura, I. Bando, J. H. Mennear, and B. K. Bernard Studies of the Toxicological Potential of Tripeptides (L-Valyl-L-prolyl-L-proline and L-Isoleucyl-L-prolyl-L-proline): IV. Assessment of the Repeated-Dose Toxicological Potential of Synthesized L-Valyl-L-prolyl-L-proline in Male and Female Rats and Dogs International Journal of Toxicology, July 1, 2005; 24(4_suppl): 25 - 39. [Abstract] [Full Text] [PDF]

				S. Mizuno, J. H. Mennear, K. Matsuura, and B. K. Bernard Studies of the Toxicological Potential of Tripeptides (L-Valyl-L-prolyl-L-proline and L-Isoleucyl-L-prolyl-L-proline): V. A 13-Week Toxicity Study of Tripeptides-Containing Casein Hydrolysate in Male and Female Rats International Journal of Toxicology, July 1, 2005; 24(4_suppl): 41 - 59. [Abstract] [Full Text] [PDF]

				T. Kurosaki, M. Maeno, J. H. Mennear, and B. K. Bernard Studies of the Toxicological Potential of Tripeptides (L-Valyl-L-prolyl-L-proline and L-Isoleucyl-L-prolyl-L-proline): VI. Effects of Lactobacillus helveticus-Fermented Milk Powder on Fertility and Reproductive Performance of Rats International Journal of Toxicology, July 1, 2005; 24(4_suppl): 61 - 89. [Abstract] [Full Text] [PDF]

				K. Matsuura, J. H. Mennear, M. Maeno, and B. K. Bernard Studies of the Toxicological Potential of Tripeptides (L-Valyl-L-prolyl-L-proline and L-Isoleucyl-L-prolyl-L-proline): VII. Micronucleus Test of Tripeptides-Containing Casein Hydrolysate and Lactobacillus helveticus-Fermented Milk Powders in Rats and Mice International Journal of Toxicology, July 1, 2005; 24(4_suppl): 91 - 96. [Abstract] [Full Text] [PDF]

				M. Maeno, S. Mizuno, J. H. Mennear, and B. K. Bernard Studies of the Toxicological Potential of Tripeptides (L-Valyl-L-prolyl-L-proline and L-Isoleucyl-L-prolyl-L-proline): VIII. Assessment of Cytotoxicity and Clastogenicity of Tripeptides-Containing Casein Hydrolysate and Lactobacillus helveticus-Fermented Milk Powders in Chinese Hamster Lung Cells International Journal of Toxicology, July 1, 2005; 24(4_suppl): 97 - 105. [Abstract] [Full Text] [PDF]

				B. K. Bernard, Y. Nakamura, K. Aihara, and J. H. Mennear Studies of the Toxicological Potential of Tripeptides (L-Valyl-L-prolyl-L-proline and L-Isoleucyl-L-prolyl-L-proline): IX. Evaluation of the Mutagenic Potential of Synthesized L-Valyl-L-prolyl-L-proline in the Salmonella-Escherichia coli/Microsome, Incorporation Assay International Journal of Toxicology, July 1, 2005; 24(4_suppl): 107 - 113. [Abstract] [Full Text] [PDF]